Boyds: New CMO
Global drug development consultancy Boyds has bolstered its clinical team with the appointment of pharmaceutical physician Dr Karen Mullen FFPM as Chief Medical Officer (CMO) and Vice President of Clinical and Medical Affairs.
Karen joins Boyds from GlaxoSmithKline, with her most recent role being Country Medical Director for the UK and Ireland, in which she led and managed a large medical department across clinical research, pharma, and vaccines. Karen’s previous roles at GSK include Head of Medical Affairs, Director of Vaccines, and Director of Metabolic Medicine.
With more than 20 years’ experience in medical affairs and drug research and development in Europe, the US, and Australia, Karen has also worked as an independent consultant providing a range of medical services to pharmaceutical companies, including Pfizer and Roche. Prior to this, Karen spent five years at Eli Lilly in various physician roles.
Karen is a Fellow of Faculty of Pharmaceutical Medicine (FFPM) and was a member of the Prescription Medicines Code of Practice Authority (PMCPA) Appeal Board for three years. Previously, she also chaired the Association of the British Pharmaceutical Industry (ABPI) Code of Practice Working Group on behalf of the Faculty of Pharmaceutical Medicine (FPM) as well as being involved in various other ABPI working groups.
At Boyds, Karen will lead the Clinical and Medical Affairs department and its team of pharmaceutical physicians, providing medical monitoring support, and safety, pharmacovigilance, scientific and medical advice across a wide range of client projects including advanced therapies and orphan drugs.